15.10
-0.12 (-0.79%)
| Penutupan Terdahulu | 15.22 |
| Buka | 14.75 |
| Jumlah Dagangan | 634,923 |
| Purata Dagangan (3B) | 1,228,479 |
| Modal Pasaran | 1,552,929,408 |
| Harga / Jualan (P/S) | 15.96 |
| Harga / Buku (P/B) | 2.97 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 Apr 2026 |
| Margin Operasi (TTM) | -340.67% |
| EPS Cair (TTM) | -2.60 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 11.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.54% |
| Nisbah Semasa (MRQ) | 6.26 |
| Aliran Tunai Operasi (OCF TTM) | -191.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -106.56 M |
| Pulangan Atas Aset (ROA TTM) | -31.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -64.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Nurix Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.0 |
| Purata | -0.38 |
|
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 1.41% |
| % Dimiliki oleh Institusi | 111.85% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 35.00 (Stifel, 131.79%) | Beli |
| 35.00 (Piper Sandler, 131.79%) | Beli | |
| Median | 30.00 (98.68%) | |
| Rendah | 26.00 (Needham, 72.19%) | Beli |
| Purata | 31.00 (105.30%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 17.59 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 29 Jan 2026 | 30.00 (98.68%) | Beli | 17.59 |
| HC Wainwright & Co. | 29 Jan 2026 | 32.00 (111.92%) | Beli | 17.59 |
| Needham | 29 Jan 2026 | 26.00 (72.19%) | Beli | 17.59 |
| Piper Sandler | 29 Jan 2026 | 35.00 (131.79%) | Beli | 17.59 |
| RBC Capital | 29 Jan 2026 | 30.00 (98.68%) | Beli | 17.59 |
| Stifel | 29 Jan 2026 | 35.00 (131.79%) | Beli | 17.59 |
| Wells Fargo | 29 Jan 2026 | 29.00 (92.05%) | Beli | 17.59 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Jan 2026 | Pengumuman | Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update |
| 14 Jan 2026 | Pengumuman | Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff |
| 12 Jan 2026 | Pengumuman | Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |